Name: UFID: PHA Exam 2. Spring 2013

Similar documents
Carbamazepine has a clearance of L/h/kg for monotherapy. For immediate release carbamazepine, the oral bioavailbility is 0.8

Thus, we can group the entire loading dose together as though it was given as a single dose, all administered when the first dose was given.

PHA 5128 Spring 2009 First Exam (Version B)

PHA 5128 Spring 2000 Final Exam

PHA 5128 Final Exam Spring 2004 Version A. On my honor, I have neither given nor received unauthorized aid in doing this assignment.

PHA Spring First Exam. 8 Aminoglycosides (5 points)

PHA Case Studies V (Answers)

TDM Lecture 7 5 th Stage. TDM of Digoxin. Uses: Digoxin is usually used in heart failure associated and atrial fibrillation.

PHA 5128 CASE STUDY 5 (Digoxin, Cyclosporine, and Methotrexate) Spring 2007

PHARMACOKINETICS SMALL GROUP II:

PHA5128 Dose Optimization II Case Study 3 Spring 2013

CLINICAL PHARMACOKINETICS INDEPENDENT LEARNING MODULE

TDM of Digoxin. Use of Digoxin Serum Concentrations to Alter Dosages

. Although there is a little

Basic Pharmacokinetic Principles Stephen P. Roush, Pharm.D. Clinical Coordinator, Department of Pharmacy

TDM of Aminoglycoside Antibiotics

Adjusting phenytoin dosage in complex patients: how to win friends and influence patient outcomes

LD = (Vd x Cp)/F (Vd x Cp)/F MD = (Css x CL x T)/F DR = (Css x (Vm-DR))/Km Css = (F x D)/(CL x T) (Km x DR)/(Vm DR)

PHA 5128 Case Study 4 (Answers) Total Cp = Unbound Cp/fu.

PHA 5127 FINAL EXAM FALL On my honor, I have neither given nor received unauthorized aid in doing this assignment.

1. If the MTC is 100 ng/ml and the MEC is 0.12 ng/ml, which of the following dosing regimen(s) are in the therapeutic window?

TDM. Measurement techniques used to determine cyclosporine level include:

Multiple IV Bolus Dose Administration

PHA 4120 Second Exam Key Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Basic Concepts of TDM

Doses Target Concentration Intervention

PHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

PHA Final Exam Fall 2006

pharmacy, we need to see how clinical pharmacokinetics fits into the pharmaceutical care process.

PHA Second Exam Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

PHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

General Principles of Pharmacology and Toxicology

PHARMACOKINETICS SMALL GROUP I:

PHA5128 Dose Optimization II Case Study I Spring 2013

PHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Case Study 2 Answers Spring 2006

Drug Dosing in Renal Insufficiency. Coralie Therese D. Dimacali, MD College of Medicine University of the Philippines Manila

PHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Aminoglycosides. Uses: Treatment of serious gram-negative systemic infections and some grampositive

TDM. Generally, hepatic clearance is determined by three main factors: These three factors can be employed in the following equation:

PHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Chapter-V Drug use in renal and hepatic disorders. BY Prof. C.Ramasamy, Head, Dept of Pharmacy Practice SRM College of Pharmacy, SRM University

The general Concepts of Pharmacokinetics

PHA Final Exam Fall 2001

PHA First Exam Fall 2003

Selected Clinical Calculations Chapter 10. Heparin-Dosing calculations

ADME Review. Dr. Joe Ritter Associate Professor of Pharmacology

Pharmacokinetics Overview

PHA First Exam. Fall 2004

SHC Vancomycin Dosing Guide

Policy: Created: 2/11/2015; Approved: Adult Pharmacokinetic Dosing and Monitoring- Vancomycin Dosing

Nonlinear Pharmacokinetics

Bassett Healthcare Clinical Laboratory

Myrna Y. Munar, Pharm.D., BCPS

Learning Outcomes. Overall Picture. Part 1 Overview of Key Concepts of Clinical Pharmacokine2cs 4/23/14. A- Awaisu- A- Nader- CPPD

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

New drugs necessity for therapeutic drug monitoring

OMCJH.CHEM.COLL.INF.1001 Therapeutic Drug Monitoring Guidelines

BASIC PHARMACOKINETICS

A Computer-based Pharmacokinetic Implementation for Digoxin Therapeutic Monitoring in Pediatric Patients

Pharmacokinetics PCTH 325. Dr. Shabbits September 12, C t = C 0 e -kt. Learning Objectives

PHAR 7632 Chapter 16

USES OF PHARMACOKINETICS

PHAR 7633 Chapter 20 Non Compartmental Analysis

BIOPHARMACEUTICS and CLINICAL PHARMACY

AMINOGLYCOSIDES TDM D O N E B Y

Drug Disposition in Obesity & Protein-Calorie Malnutrition

A REVIEW ON DOSAGE REGIMEN

4WS Neurology. Table of Contents

Target Concentration Intervention

Each tablet contains:

General Principles of Pharmacology and Toxicology

C OBJECTIVES. Basic Pharmacokinetics LESSON. After completing Lesson 2, you should be able to:

Nontraditional PharmD Program PRDO 7700 Pharmacokinetics Review Self-Assessment

Metabolism. Objectives. Metabolism. 26 July Chapter 28 1

Determination of bioavailability

Pharmacokinetics Applied to the Treatment of Asthma

Clinical Pharmacokinetics. Therapeutic Drug Monitoring of Phenytoin

PHENYTOIN DOSING INFORMATION. Adult Dosage

Principal Investigator: Marion, Alan, S, M.D., MDS Pharma Services (US) Inc., 621 Rose Street, PO Box 80837, Lincoln, NE 68502, USA

Principles of Pharmacokinetics

PHA Exam 1. Spring 2013

Complicated Withdrawal

Renal Excretion of Drugs

Drug dosing in Extremes of Weight

Career Corner: Pharmaceutical Calculations for Technicians. Ashlee Mattingly, PharmD, BCPS

Pharmacokinetic Models Using Ordinary Differential Equations* DRUG DISTRIBUTION COMPARTMENTAL ANALYSIS OF DRUG DISTRIBUTION

Introduction to. Pharmacokinetics. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D

Section 5.2: Pharmacokinetic properties

Principles of Medication Use in Older Adults ANNE L. HUME, PHARMD PROFESSOR OF PHARMACY UNIVERSITY OF RHODE ISLAND

Effects of Liver Disease on Pharmacokinetics

Tala Saleh. Abdul Aziz ALShamali. Abdul Aziz ALShamali

Pharmacokinetics for Physicians. Assoc Prof. Noel E. Cranswick Clinical Pharmacologist Royal Children s Hospital Melbourne

(Max 2 g) = to nearest 250 mg

NONLINEAR PHARMACOKINETICS: INTRODUCTION

ICU Volume 11 - Issue 3 - Autumn Series

COMPARTMENTAL ANALYSIS OF DRUG DISTRIBUTION

Adult Institutional Pharmacokinetics Protocol

ANTIBIOTIC DOSE AND DOSE INTERVALS IN RRT and ECMO

Transcription:

PHA 5128 Exam 2 Spring 2013 1 Carbamazepine (5 points) 2 Theophylline (10 points) 3 Gentamicin (10 points) 4 Drug-drug interaction (5 points) 5 Lidocaine (5 points) 6 Cyclosporine (5 points) 7 Phenobarbital (5 points) 8 Renal Disease (5 points) 9 Basic PK (5 points) 10 Methotrexate (10 points) 11 Bioavailability (5 points) 12 Procainamide (10 points) 13 Phenytoin (10 points) 14 Digoxin (10 points) Total Points: 100

Problem 1 (5 points) Carbamazepine is a lipid soluble anti-epileptic drug that has a large volume of distribution in obese patients. Which of the following statements is true of the expected carbamazepine disposition in obese patients? A. The elimination half-life in obese patients is expected to be decreased. B. The elimination half-life in obese patients is expected to be increased. C. As a result the elimination half-life in obese patients is expected to remain the same. D. Its volume of distribution is expected to decrease. E. None of the above statements is true. Solution: t1/2 = 0.693*Vd/CL

Problem 2 (10 points) Sophia is a 2-year-old, 12 kg girl in the PICU who is placed on a theophylline drip at 1 mg/kg/hr after first receiving a 5 mg/kg bolus at 10 am. The drug level was monitored and listed in the table below. Time Concentration 11 am 8.2 mg/l 7 pm 13.7 mg/l What is the half-life of theophylline in this girl? A. 1 h B. 3 h C. 6 h D. 9 h E. 12 h Solution: CL 2 R 2 Vd ( C C ) 2 1 12 2 0.5 12 (8.2 13.7) ( C C ) ( C C ) ( t t ) (8.2 13.7) (8.2 13.7) (19 11) 0 1 2 1 2 1 2 2 1 Vd 0.5 12 6L k e CL 0.7 0.117h Vd 6 1 0.693 0.693 t1/2 5.9h 6h k 0.117 e 0.7 L h

Problem 3 (10 points) C.D. is a 60 years old, 6 2 tall and 185 lbs weight male patient who suffers post-surgical wound infection and has been treated with gentamicin for several days. His serum creatinine is 1.5 mg/dl. The gentamicin is given IV infusion over 15 min with dose of 6 mg/kg once daily. Which of the following is close to the measured peak concentration that was taken 90 min after the infusion was started? (Please use ke=cl/vd) A. 30 mg/l B. 25 mg/l C. 20 mg/l D. 15 mg/l E. The information provided is not enough to calculate the peak concentration at steady state. Solution: IBW=50+2.3(height in inches-60)=50+2.3(74-60)=50+32.2=82.2 kg TBW IBW 185 2.2 100% 102.3% 120% TBW will be used to calculate creatinine clearance 82.2 (140 60) 185 (140 age) BW CL CL 2.2 cr 62.3ml min 3.7 L h Cp 72 1.5 72 Vd 0.25 L kg 185 kg 21.0L 2.2 k e cr CL 3.7 0.176h Vd 21.0 τ=24h and T=0.25h 1

C 185 Dose 6 2.2 23.9 mg L 1 e 1 e Vd ke T ( ) 21.0 0.176 0.25 ( ) kt e 0.176 0.25 1 e 1 e max ke 0.176 24 t1=1.25h, C C e e mg L mg L kt e 1 0.176 1.25 max max 23.9 19.2 20 Problem 4 (5 points) Which of the following combination is TRUE of triazolam metabolism and drug-drug interaction? 1) Based on the graphs above, rifampin induces the metabolism of triazolam 2) Based on the graphs above, ritonavir induces the metabolism of triazolam 3) Based on the graphs above, rifampin inhibits the metabolism of triazolam 4) Based on the graphs above, ritonavir inhibits the metabolism of triazolam 5) Metabolic enzyme inducers can increase the enzyme expression level through various mechanisms, including increasing transcription, decreasing mrna degradation, etc.

6) There are only two types of metabolic enzyme inhibition, which are competitive and noncompetitive inhibition. A. 1, 4, 5&6 B. 2, 3, 5&6 C. 1, 4 &5 D. 2, 3 &5 E. 1&4 Problem 5 (5 points) J.D, a 72 kg, 35 years old man, was admitted to the hospital for his liver cirrhosis. What is the loading IV dose of lidocaine to achieve the plasma level of 4 mg/l and what is the infusion rate of lidocaine to maintain the concentration to 4 mg/l? A. LD is 200 mg and MD is 100 mg B. LD is 200 mg and MD is 120 mg C. LD is 170 mg and MD is 100 mg D. LD is 170 mg and MD is 120 mg E. LD is 100 mg and MD is 120 mg Solution: Vc 0.6 72 43.2L We used the initial distribution because we are calculating the loading IV dose. Vc Cp 43.2 4 LD 198.6 mg 200 mg F S 1 0.87 CL 0.36 72 25.9 L h D Css CL 4 25.9 MD 119.1 mg h 120 mg h S F 0.87 1

Problem 6 (5 points) A 65 kg liver transplant patient was receiving 300 mg QD cyclosporine with IV infusion. His plasma concentration at steady state was 160 ng/ml. Since his hepatic function tests appear to be fine, the physician would like to change the IV infusion to oral administration and adjust the steady state concentration to be 130 ng/ml. What would be an appropriate oral dose for him? A. 90 mg/day B. 600 mg/day C. 800 mg/day D. 900 mg/day E. 1000 mg/day Solution: Cssdesired Fcurrent 130 1 Dosenew Dosecurrent 300 812.5 800mg day Css F 160 0.3 Current new

Problem 7 (5 points) J.D. is a 2-week-old neonate, 4 kg in weight has developed tonic-clonic seizure activity and was administered phenobarbital sodium intravenous infusion. Half-way through the dosing interval (Css,ave) after 8 weeks of dosing at 5.1 mg every 12 hours, his blood concentration of phenobarbital was 23 mg/l. Determine J.D. s phenobarbital clearance. Assume that steady-state is achieved. A. 0.89 L/hr/kg B. 1.7 L/hr/kg C. 0.017 L/hr/kg D. 12 L/hr/kg E. 0.00416 L/hr/kg Solution: CL = S F Dose τ C ss,ave CL by weight = = 0.9 1 23 0.0166 L/hr 4 kg 5.1 12 = 0.017 L hr = 0.00416 L/hr/kg

Problem 8 (5 points) Which combination of the following factors makes the serum creatinine level a good choice to estimate renal function? 1) Creatinine is endogenous 2) Creatinine is only eliminated by the kidney 3) Creatinine urinary excretion rate is not affected by diseases 4) Creatinine is bound to protein in plasma 5) Creatinine is usually constantly formed by muscle A) 1, 2 & 5 B) 1, 2, 3 & 5 C) 1, 2, 4 & 5 D) 1, 3, 4 & 5 E) All of the factors make the serum creatinine level a good choice to estimate renal function.

Problem 9 (5 points) Select all TRUE statements. 1) Clearance can be thought of as a volume of plasma from which the drug is removed in a specific time period. 2) If elimination from the central/body compartment is first order we can assume that a one compartment pharmacokinetic model is applicable. ke t 3) Given Cp Cp0 e, and two data points (t1, Cp1) and (t2, Cp2), the elimination rate constant can be calculated as the slope equals to -(lncp2-lncp1)/(t2-t1). 4) If the infusion rate constant (k0) is doubled the steady state plasma concentration (Cpss) will be doubled, assuming the other parameters are unchanged. 5) Appropriate unit for AUC is mg hr L. A. 1, 2, 3 & 4 B. 2, 3, 4 & 5 C. 1, 2, 3

D. 1, 3, 4 E. All the statements are true. Problem 10 (10 points) V.A., a 25-year-old, 61-kg woman (non-obese, SCr = 1.2 mg/dl) is to receive a course of methotrexate (MTX) therapy for acute lymphoblastic leukemia. Her regimen will consist of an IV infusion of 40 mg/h for 36 hours. Calculate her anticipated MTX plasma level (in μm) 60h after the beginning of the infusion. You may assume that steady state has been achieved after 24h. A. 0.15 μm B. 0.25 μm C. 0.35 μm D. 0.45 μm E. 0.55 μm Solution:

(140 age)(weight in kg) CL Cr = = 85(SCr SS ) (140 25)(61) 85(1.2) = 68.8 ml min = 4.1 L h CL MTX = (1.6)CL Cr = (1.6)4.1 L h = 6.6 L h C 36 = C ss,avg = Dose τ CL = 40mg (1h) (6.6 L = 6.1 mg h ) L 6.1 mg L = 13.4μM Let t* be the time (after stop of the infusion) that is required to for MTX concentration to fall to 0.5 μm. t = ln ( 13.4μM 0.5μM ) 0.231 1 h = 14.2h Problem 11 (5 points) 60h 36h 14.2h = 9.8h k e (< 0.5μM) = ln(2) 10h = 0.0693 1 h C 60 = C 50.2 (e 0.0693 9.8h ) = 0.5μM(e 0.0693 9.8h ) = 0.25μM In general, what is NOT the reason that an oral dosage form will have <100% bioavailability: A. Poor solubility/dissolution rate B. First-pass effect C. Poor permeability D. Low volume of distribution E. All above are the reasons that an oral dosage form will have <100% bioavailability.

Problem 12 (10 points) T.H. is a 43-year-old, 45 kg weight female with serum creatinine of 1.7 mg/dl. She is hospitalized with congestive heart fainlure and procainamide is recommended by the physician. What is the half-life of procainamide in this patient? A. 0.1h B. 1.5h C. 3h D. 4h E. 8h Solution:

(140 age) BW (140 43) 45 CLcr 30.2 ml min =1.8 L h Cp 85 1.7 85 cr CL 3 CL 3 1.8 5.4 L h renal cr CL 0.13 BW 0.13 45 5.9 L h acetylation CL 0.1 BW 0.1 45 4.5 L h other CL CL CL CL 5.4 5.9 4.5 15.8 L h total renal acetylation other Because of CHF, CL 15.8 / 2 7.9 total Vd 2 45 90L k e CL 7.9 0.088h Vd 90 1 0.693 0.693 t12 7.9h 8h k 0.086 e Problem 13 (10 points) T.M., a 39-year-old, 60kg female, had been taking 220mg/day of sodium phenytoin; however, her dose had been increased to 300mg/day because her seizures were poorly controlled and because her phenytoin plasma concentration was only 2.6mg/L. Now she complains about minor CNS side effects and her measured plasma phenytoin concentration is 26mg/L. This level was decided to be too high for this patient, so the maintenance dose was discontinued. How long would it take for the phenytoin concentration to drop to 15 mg/l after discontinuation of dose? The following equation may be helpful to solve this problem: T = (K M ln ( C 0 C ) + (C 0 C)) V d V max

A. 1.6 h B. 1 day C. 30.3 h D. 37.7 h E. 45.1 h Solution: V max = (D 1) (D 2 ) (C 2 C 1 ) C 2 (D 1 ) C 1 (D 2 ) V d = 0.65 L 60 kg = 39 L kg = 220 300 (26 2.6) 26 220 2.6 300 K M = C 1 (V max D 1 ) 2.6 (313 220) = = 1.1 mg/l D 1 220 V d T = (K M ln ( C 0 C ) + (C 0 C)) V max S = 1.57 days 24 = 37.7 h mg = 313 (sodium phenytoin) day = (1.1 ln (26 15 ) + (26 15)) 39 313 0.92 Problem 14 (10 points) A.P., a 55-year-old, 90-kg man, 6 2, was admitted with complaints of increased shortness of breath and yellow sputum production. He has a medical history of congestive heart failure. During his hospital stay, he developed atrial fibrillation and was given digoxin to slow his ventricular rate. He received 0.75-mg digoxin IV at 9pm on day 1 and was given a maintenance dose of 0.2-mg IV each morning (starting at 9am on day 2). His serum creatinine is stable at 1.7 mg/dl. Calculate his anticipated digoxin plasma concentration at 9am on day 4. A. 1.0 μg/l B. 1.3 μg/l

C. 1.6 μg/l D. 2.0 μg/l E. 2.3 μg/l Solution: Thus, the patient is non-obese. CL Cr = IBW male = 50kg + 2.3kg(14) = 82.2kg TBW < IBW 1.2 = 98.7kg (140 age)(bw) 72(SCr SS ) = (140 55)(90) 72(1.7) = 62.5 ml min VD[L] = 3.8(BW in kg) + 3.1(CL Cr in ml/min) = 3.8 90 + 3.1 62.5 536 L CL CHF [ ml min ] = 0.33(BW in kg) + 0.9 (CL Cr in ml ) = 0.33 90 + 0.9 62.5 min 86 ml min = 5.2 L h = 124 L day k e = CL L 124 VD = day 536 L = 0.231 1 day C Sum = D 1 V e k et 1 + D 2 V e k et 2 + D 3 V e k et 3 = 750μg 1 536L e 0.231 day 2.5days + 200μg 1 536L e 0.231 day 2days + 200μg 536L e 0.231 1 day 1day = 1.3 μg L